# Alkermes plc (ALKS) Stock Analysis: Strong Buy Ratings and Promising Growth Potential

- Link: https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-strong-buy-ratings-and-promising-growth-potential/4121253235
- Published: 2026-06-08T10:21:48+01:00
- Author: Madison Wilson

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector, is attracting
significant attention from investors, thanks to its robust revenue growth and strong
analyst ratings. With a market capitalization of $7.13 billion, this Ireland-based
biopharmaceutical company is making waves in the specialty and generic drug manufacturing
industry by addressing unmet medical needs across multiple therapeutic areas.

Currently trading at $42.80, Alkermes’ stock has experienced an impressive 52-week
range, climbing from $26.13 to a recent high of $43.38. Despite a minor recent price
change of -0.58 (-0.01%), the stock’s upward trajectory is underscored by its significant
revenue growth of 28.20%. This growth is reflective of the company’s strong product
portfolio, which includes treatments for opioid and alcohol dependence, schizophrenia,
and bipolar I disorder, as well as its exciting pipeline of products targeting neurological
disorders.

Alkermes’ financial metrics reinforce its growth narrative. Although the trailing
P/E ratio and PEG ratio are unavailable, the forward P/E of 18.18 provides a glimpse
into potential future earnings performance, suggesting a reasonable valuation given
the company’s growth prospects. Additionally, with a return on equity of 9.36% and
a free cash flow of over $140 million, Alkermes is well-positioned to reinvest in
its innovative product pipeline and maintain its competitive edge.

Analysts are bullish on Alkermes, with 14 buy ratings, 3 hold ratings, and no sell
ratings. The stock’s average target price of $45.44 indicates a potential upside
of 6.16%, offering an attractive opportunity for investors seeking growth in the
healthcare sector. The target price range of $34.00 to $59.00 further highlights
the stock’s potential to reward patient investors.

Technical indicators paint a favorable picture for Alkermes as well. The stock is
trading above both its 50-day moving average of $35.82 and its 200-day moving average
of $31.50, signaling a strong upward trend. The RSI (14) of 18.61 suggests the stock
is currently in oversold territory, potentially indicating a buying opportunity 
for investors looking to capitalize on any short-term price fluctuations. Additionally,
the MACD of 2.13 surpassing the signal line of 1.72 reinforces the positive momentum.

Despite its promising financial and technical performance, Alkermes does not currently
offer a dividend yield, with a payout ratio of 0.00%. This is in line with the company’s
strategy to reinvest earnings into research and development, ensuring continuous
innovation and expansion of its therapeutic offerings.

With collaborations with industry giants like Janssen Pharmaceutica, Alkermes is
well-positioned to leverage its proprietary technology platforms and broaden its
market reach. Founded in 1987 and headquartered in Dublin, Ireland, Alkermes continues
to be a formidable force in the biopharmaceutical landscape, committed to improving
patient outcomes and delivering shareholder value.

For investors seeking exposure to the healthcare sector with a focus on growth, 
Alkermes plc presents a compelling opportunity. Its strong buy ratings, impressive
revenue growth, and strategic collaborations position it as a noteworthy contender
in the biopharmaceutical industry.

Share on: